Print

Oxygen Biotherapeutics, Inc. (OXBO) Strengthens Balance Sheet Through $4.6 Million Debt Conversion  
9/18/2013 10:05:29 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MORRISVILLE, N.C.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a developer of oxygen-carrying therapeutics, today announced the Company has converted $4.6 million in outstanding principal amount of a convertible promissory note. The note, which was scheduled to mature on July 1, 2014, carried an interest rate of 15% per annum. This move reduces the Company’s debt from $4.9 million to $300,000. The Company estimates that this will improve its net shareholder equity by approximately $3.5 million.

Help employers find you! Check out all the jobs and post your resume.

//-->